Market Overview

UPDATE: Goldman Sachs Upgrades Amgen to CL-Buy on Favorable Catalysts, Upside Potential

Share:
Related AMGN
A Look At Nvidia's Largest Shareholders And What Their Presence Means
Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected
Top Cloud Software Firm Has Flipped Switch, Boasts 2 FANG Clients (Investor's Business Daily)

In a report published Wednesday, Goldman Sachs analyst Terence Flynn upgraded the rating on Amgen (NASDAQ: AMGN) from Neutral to Conviction List Buy, and raised the price target from $100.00 to $130.00.

In the report, Flynn noted, “We switch to AMGN from BIIB, as we see a more favorable combination of catalysts and upside potential. AMGN is entering a period where several of its key biologic franchises are coming off patent between 4Q13 and 2H15. However, we believe this is anticipated by investors and for the most part already reflected in consensus estimates. We project that AMGN's pipeline (key readouts in 1Q14-2015) and own biosimilars (first launch in 2017) will allow it to replace the potential revenue that could be lost to competition and grow its base.”

Amgen closed on Tuesday at $104.21.

Latest Ratings for AMGN

DateFirmActionFromTo
Apr 2017JefferiesDowngradesBuyHold
Mar 2017UBSInitiates Coverage OnNeutral
Feb 2017Bank of AmericaUpgradesNeutralBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!